Saliva CA125 and TPS levels in patients with oral squamous cell carcinoma

被引:18
作者
Geng, Xue-fei [1 ]
Du, Meng [1 ]
Han, Jing-xiu [2 ]
Zhang, Min [3 ]
Tang, Xiao-fei [4 ]
Xing, Ru-dong [1 ]
机构
[1] Capital Med Univ, Sch Stomatol, Dept Oral & Maxillofacial Surg, Beijing 100050, Peoples R China
[2] Chinese Ctr Dis Control & Prevent, Beijing, Peoples R China
[3] Capital Med Univ, Sch Stomatol, Inst Dent Res, Beijing 100050, Peoples R China
[4] Capital Med Univ, Sch Stomatol, Dept Oral Pathol, Beijing 100050, Peoples R China
关键词
Carbohydrate antigen 125 (CA125); Tissue polypeptide-specific antigen (TPS); Saliva; Tumor marker; Oral squamous cell carcinoma (OSCC); PROGNOSTIC-FACTORS; TUMOR-MARKERS; CA-125; GENE; CYFRA; 21-1; CANCER; SERUM; CEA;
D O I
10.5301/jbm.5000001
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Objectives: To determine the levels of carbohydrate antigen 125 (CA125) and tissue polypeptide-specific antigen (TPS) in saliva of patients with oral squamous cell carcinoma (OSCC) and patients with nonneoplastic disease of the oral cavity, and to investigate their diagnostic value and their relationship with pathological grade and clinical stage. Methods: A total of 97 hospitalized patients with OSCC, 36 patients with nonneoplastic disease of the oral cavity and 50 healthy individuals were included in this investigation. Mixed saliva was collected from these patients and the healthy controls before treatment. Saliva samples were analyzed by enzyme-linked immunosorbent assay (ELISA). Results: The saliva CA125 and TPS concentrations were significantly higher in patients with OSCC than in patients with nonneoplastic disease and healthy controls, but not significantly different between patients with nonneoplastic disease and controls. Neither the saliva CA125 nor the TPS level was correlated with pathological grade and clinical stage. The sensitivity, specificity and accuracy of saliva CA125 and TPS for the diagnosis of OSCC were 80.0%, 66.0%, 75.7%, and 82.1%, 74.0%, 79.3%, respectively. When CA125 and TPS were analyzed independently, there was no significant difference in sensitivity, specificity and accuracy between the two markers. When CA125 and TPS were analyzed in combination, there was no significant difference in sensitivity, specificity and accuracy between independent detection and combined detection. Conclusions: The saliva CA125 and TPS concentrations were elevated in patients with OSCC. CA125 and TPS may prove to be useful tumor markers in OSCC.
引用
收藏
页码:216 / 220
页数:5
相关论文
共 28 条
[1]   Clinical utility of cytokeratins as tumor markers [J].
Barak, V ;
Goike, H ;
Panaretakis, KW ;
Einarsson, R .
CLINICAL BIOCHEMISTRY, 2004, 37 (07) :529-540
[2]   REACTIVITY OF A MONOCLONAL-ANTIBODY WITH HUMAN OVARIAN-CARCINOMA [J].
BAST, RC ;
FEENEY, M ;
LAZARUS, H ;
NADLER, LM ;
COLVIN, RB ;
KNAPP, RC .
JOURNAL OF CLINICAL INVESTIGATION, 1981, 68 (05) :1331-1337
[3]   ANTIGENICITY OF POOLED HUMAN MALIGNANT AND NORMAL TISSUES BY CYTO-IMMUNOLOGICAL TECHNIQUE - PRESENCE OF AN INSOLUBLE, HEAT-LABILE TUMOR ANTIGEN [J].
BJORKLUND, B ;
BJORKLUND, V .
INTERNATIONAL ARCHIVES OF ALLERGY AND APPLIED IMMUNOLOGY, 1957, 10 (03) :153-184
[4]  
BJORKLUND B, 1990, J NUCL MED ALLIED S, V34, P203
[5]  
Bremer K, 1996, ANTICANCER RES, V16, P905
[6]  
DAOUD E, 1991, CLIN CHEM, V37, P1968
[7]  
Gaston KE, 2010, METHODS MOL BIOL, V641, P303, DOI 10.1007/978-1-60761-711-2_17
[8]   Synergistic effect of cigarette smoke and saliva on lympho-cytes - the mediatory role of volatile aldehydes and redox active iron and the possible implications for oral cancer [J].
Hasnis, E ;
Reznick, AZ ;
Pollack, S ;
Klein, Y ;
Nagler, RM .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2004, 36 (05) :826-839
[9]   Prognostic factors in tongue cancer - relative importance of demographic, clinical and histopathological factors [J].
Kantola, S ;
Parikka, M ;
Jokinen, K ;
Hyrynkangs, K ;
Soini, Y ;
Alho, OP ;
Salo, T .
BRITISH JOURNAL OF CANCER, 2000, 83 (05) :614-619
[10]   Tissue polypeptide-specific antigen (TPS) determinations before and during intermittent maximal androgen blockade in patients with metastatic prostatic carcinoma [J].
Kil, PJM ;
Goldschmidt, HMJ ;
Wieggers, B ;
Kariakine, OB ;
Studer, UE ;
Whelan, P ;
Hetherington, J ;
de Reijke, TM ;
Hoekstra, JW ;
Collette, L .
EUROPEAN UROLOGY, 2003, 43 (01) :31-37